Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA)New Phase 1b data further illustrate potential of salanersen in SMA, ...
The US Food and Drug Administration (FDA) has rejected Biogen’s high-dose Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA). The agency chose to decline the antisense ...
Biogen (NasdaqGS:BIIB) has appointed Dr. Maria C. Freire as Chair of its Board of Directors. Dr. Freire brings experience in biomedical research, drug development, and public private partnerships. The ...
If Novo Nordisk A/S’s wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer’s disease, Biogen Inc.’s Chief Executive Officer Chris Viehbacher doesn’t see it as a ...
Biogen Inc. (NASDAQ:BIIB) on Wednesday announced in a press release the topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being developed for ...
Biogen BIIB announced that the European Commission (“EC”) has approved Zurzuvae (zuranolone) to treat postpartum depression (PPD) in adults after childbirth. Following this approval, Zurzuvae became ...
The Alzheimer's drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis. Biogen on Friday said fiscal 2025 revenue from ...
The Food and Drug Administration on Monday approved Biogen's Alzheimer's disease drug aducanumab, making it the first medication cleared by U.S. regulators to slow cognitive decline in people living ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results